Drug intelligence / Profile preview

epiutide

Development stage: Unknown
Lead developer: Wuhan Yicheng Biotechnology
Modality: Peptides
Administration: Ophthalmic

Overview

Epiutide is a synthetic peptide therapeutic developed by Wuhan Yicheng Biotechnology for the treatment of allergic conjunctivitis. Formulated as an ophthalmic solution, it is designed to modulate the allergic response by targeting the IgE-mediated pathway. Specifically, it is intended to inhibit the interaction between Immunoglobulin E (IgE) and its high-affinity receptor (FcεRI) on mast cells and basophils, thereby preventing the release of inflammatory mediators like histamine. The drug has been investigated in Phase 2 clinical trials in China to evaluate its safety and efficacy in patients with allergic conjunctivitis.

Other names: 奕优肽

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on epiutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epiutide.

Explore the full profile